PLI Pharma Categories 1 / 2 / 3: Differential Eligibility Rules

A Tier 2 pharma applicant of the scale of a Suven Life Sciences — with a candidate product portfolio that straddles complex generics, APIs and repurposed drugs, and a corporate footprint that includes contract research, contract manufacturing, and small-scale API supply into both the Indian formulation market and the export CRAMS chain — evaluates its FY 2026-27 application to the Department of Pharmaceuticals PLI Pharma Rs 15,000 crore scheme. The applicant must decide between the Category 1 complex-generics product basket, the Category 2 API and Key Starting Material product basket, and the Category 3 repurposed-drug and in-vitro diagnostic product basket. Each category carries a distinct product-basket admission test, a distinct FY 2019-20 base-year eligibility check, a distinct incentive-rate schedule across the six-year window, and a distinct per-applicant per-year cap. Layered on top is the Section 115BAA versus Section 35(2AB) trade-off, which for a Category 1 R&D-heavy applicant can cost 4 to 6 percentage points of effective tax on the R&D pool if the concessional-regime opt-in is chosen without modelling first. This is PLI Pharma Categories 1 2 3 eligibility differential at operating scale, and the decision matrix that separates a defensible category recommendation from one that under- or over-states the scheme-window disbursement forecast by tens of crores runs five parallel evaluation layers per candidate product basket.

Quick reference

The reconciliation in one paragraph

A pharma applicant evaluating PLI Pharma entry runs a five-layer category-selection decision matrix per candidate product basket. Layer one is product-basket fitment against the DoP scheme definitions — Category 1 complex-generics, Category 2 API-and-KSM, Category 3 IVD-and-repurposed-drug. Layer two is FY 2019-20 base-year sales reconstruction per candidate product from the SAP FI material ledger with GSTR-1 cross-validation and audited-financial-statement tie-out. Layer three is the category-specific eligibility gate — the 50 percent Domestic Value Addition floor for Category 2 KSM candidates, the export-commitment threshold for Category 3 medical-device candidates, the complex-generics or patented-drug definitional test for Category 1 candidates. Layer four is the incentive-rate arithmetic applied to a plausible six-year incremental-sales trajectory, with the per-applicant per-year cap binding explicitly quantified and the excess incentive foregone modelled. Layer five is the Section 115BAA opt-in impact model — the effective-tax comparison between the normal regime (Section 35(2AB) weighted deduction preserved, Section 115JB MAT exposure on the PLI grant) and the concessional 22 percent regime (Section 35(2AB) forfeited, MAT exempt). Each layer is a distinct reconciliation and the five aggregate to a ranked category recommendation per candidate product basket that hands over cleanly to the operational PLI claim workflow once the applicant enters the scheme.

What the scenario looks like in India — the illustrative persona

The Tier 2 pharma applicant universe in India runs the mixed-portfolio profile that makes PLI category selection a live decision rather than a mechanical fitment. Suven Life Sciences (and its sibling entity Suven Pharmaceuticals, the demerged formulations arm) — with the Pashamylaram, Suryapet and Hyderabad campuses in Telangana — sits in this profile: some product lines that could fit Category 1 (specialty formulations, complex-generics candidates), some that fit Category 2 (contract-manufactured APIs and Drug Intermediates for global innovator programmes), and some that could fit Category 3 (repurposed-drug candidates from the CNS research pipeline). Neuland Laboratories (with its Bonthapally and Pashamylaram plants in Telangana) sits in a similar profile with an API-heavy portfolio that leans Category 2 but with select CGT precursor and orphan-drug intermediate candidates that could argue for Category 1 fitment. Divi’s Laboratories (with the Vishakhapatnam and Bollaram API campuses in Andhra Pradesh and Telangana) is more clearly Category 2 with its bulk-drug scale. Wockhardt straddles Category 1 formulations and Category 3 medical devices. Cadila Pharmaceuticals, JB Chemicals, Ajanta Pharma and Ipca Labs each present variations of the mixed-portfolio profile that make the category-selection matrix a live analytical exercise per scheme cycle.

For the illustrative worked example in this article, we take a Tier 2 pharma applicant at the scale of a Suven Life Sciences with a candidate product portfolio of eight molecules — three that could fit Category 1 (complex-generics injectables, orphan-drug candidate), three that fit Category 2 (contract-manufactured APIs supplied into global innovator supply chains), and two that fit Category 3 (repurposed-drug candidates from the CNS research programme, IVD reagent kit). The persona is illustrative; real PLI Pharma applicant portfolios, category selections and DoP-approved product baskets are disclosed only in aggregate by the Department of Pharmaceuticals and are not the subject of speculative recomputation here. The point of the persona is the decision-matrix surface, not the identity of any specific real applicant.

The regulatory overlay — DoP scheme guidelines, Ind AS 20, Section 115BAA, Section 35(2AB), Section 92BA

The PLI Pharma scheme guidelines notified by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers set out the three-category structure with distinct eligibility criteria and distinct incentive-rate schedules. Category 1 targets the complex-generics, patented-drugs, cell-and-gene-therapy, orphan-drug and rare-disease-drug universe — the highest-value therapy segment where the scheme intent is to build domestic capability in the therapy classes that India currently imports or under-produces. The Category 1 incentive rate schedule is 10 percent of eligible incremental sales for Years 1 through 4, 8 percent in Year 5 and 6 percent in Year 6, typically capped at Rs 100 crore per applicant per year. Category 2 targets the API, KSM and Drug Intermediate universe — the raw-material and building-block layer of the pharma value chain, where the scheme intent is to reduce import dependence on China for critical inputs. The Category 2 incentive rate schedule is 10 percent for Years 1 and 2, 8 percent for Years 3 and 4 and 6 percent for Years 5 and 6, with the KSM leg subject to a 50 percent Domestic Value Addition floor. Category 3 targets the in-vitro diagnostic, repurposed-drug and medical-device universe with a flat 5 percent incentive rate across the entire six-year window and the widest product-basket admission. Full walk-through of the Category 1 flow at operating scale sits in the PLI Pharma Rs 15,000 crore eligibility and incremental sales reconciliation cornerstone.

Section 115BAA of the Income-tax Act 1961 offers a concessional 22 percent corporate tax rate (plus applicable surcharge and cess) in exchange for forgoing specified deductions including the Section 35(2AB) weighted deduction for scientific research on DSIR-approved in-house R&D facilities. Section 115BAA also brings exemption from Section 115JB Minimum Alternate Tax. The trade-off is category-dependent: a Category 1 applicant developing complex generics or biosimilars runs a large R&D pool that generates substantial Section 35(2AB) weighted-deduction claims, and the concessional-regime opt-in can cost 4 to 6 percentage points of effective tax on the R&D pool; a Category 3 applicant on repurposed drugs or IVDs typically has a smaller Section 35(2AB) claim and the Section 115BAA opt-in is more clearly accretive. The full mechanic of the Section 35(2AB) claim cycle sits in the Section 35(2AB) weighted deduction pharma R&D reconciliation guide.

Ind AS 20 (Accounting for Government Grants and Disclosure of Government Assistance) governs the recognition and presentation of the PLI grant across all three categories. The grant is a grant related to income, recognised in profit or loss on a systematic basis matching the periods in which the applicant recognises the related costs. Presentation choice permits recognition as other income on a separate line or netting against the related expense. The category selected affects the grant-recognition volatility — Category 1 with its Rs 100 crore per-applicant per-year cap has more year-to-year volatility (the cap can bind in one year and not the next depending on incremental-sales trajectory) than Category 3 with its flat 5 percent rate. Section 92BA specified-domestic-transaction and Rule 10D transfer-pricing documentation applies to any intra-group transfer between a Category 1 formulation entity and a Category 2 API sister entity in the same corporate group — the intra-group transfer volume must be documented and its treatment in each entity’s incremental-sales computation must be exposed.

A worked example — a Tier 2 pharma applicant evaluating FY 2026-27 category selection

Illustrative — the following figures represent the operating pattern of a Tier 2 pharma applicant of the scale of a Suven Life Sciences evaluating PLI Pharma category selection at scheme entry. Public disclosures do not reveal candidate product portfolios, category-selection recommendations, or Section 115BAA opt-in decisions at this level of detail; the numbers below are illustrative of the decision-matrix surface, not a claim about any specific real applicant’s PLI position.

The applicant’s candidate product register lists eight molecules. Category 1 candidates: complex-generics injectable A (FY 2019-20 base Rs 45 crore illustrative), complex-generics injectable B (base Rs 32 crore), orphan-drug candidate C (base Rs 18 crore) — aggregate Cat 1 base Rs 95 crore. Category 2 candidates: contract-manufactured API D (base Rs 65 crore), contract-manufactured KSM E (base Rs 48 crore), Drug Intermediate F (base Rs 27 crore) — aggregate Cat 2 base Rs 140 crore. Category 3 candidates: repurposed-drug candidate G (base Rs 12 crore), IVD reagent kit H (base Rs 8 crore) — aggregate Cat 3 base Rs 20 crore.

The applicant models a plausible six-year incremental-sales trajectory per category and applies the category-specific incentive-rate schedule with the per-applicant per-year cap binding. The Category 1 basket delivers incremental sales that peak at Rs 620 crore in Year 4 — raw incentive at 10 percent = Rs 62 crore, comfortably below the Rs 100 crore Cat 1 cap; the six-year cumulative Cat 1 incentive is illustratively Rs 195 crore. The Category 2 basket delivers incremental sales that peak at Rs 480 crore in Year 3 — raw incentive at 8 percent = Rs 38 crore; the six-year cumulative Cat 2 incentive is illustratively Rs 155 crore. For the Cat 2 KSM leg, the DVA computation must clear the 50 percent floor annually; the illustrative KSM E historical DVA is 62 percent, giving a 12-point headroom against the floor. The Category 3 basket delivers incremental sales that peak at Rs 85 crore in Year 5 — flat 5 percent incentive = Rs 4.25 crore; the six-year cumulative Cat 3 incentive is illustratively Rs 22 crore.

The Section 115BAA opt-in impact model runs the effective-tax comparison per scenario. Under the normal regime, the applicant claims Section 35(2AB) weighted deduction on its DSIR-approved R&D expenditure (Cat 1 basket carries an illustrative R&D pool of Rs 85 crore per year; Cat 2 carries Rs 22 crore; Cat 3 carries Rs 4 crore), and pays Section 115JB MAT at 15 percent of book profit (plus surcharge and cess) with the PLI grant income adding to book profit. Under the Section 115BAA concessional regime, the Section 35(2AB) weighted deduction is forfeited entirely, MAT is exempt, and the flat 22 percent (plus surcharge and cess) applies to computed taxable income including PLI grant. For the Cat 1 + Cat 2 scenario with a combined R&D pool of Rs 107 crore, the Section 35(2AB) preservation is worth an illustrative 4.8 percentage points of effective tax on the R&D pool — the concessional-regime opt-in destroys value at this R&D scale and the recommendation is to stay under the normal regime with the MAT exposure on the PLI grant absorbed as a modelled provision.

The final category-selection recommendation, before Section 92BA intra-group transfer analysis for the Cat 1 formulation-plus-Cat 2 API pair, is Cat 1 + Cat 2 parallel approvals with the normal tax regime retained. Total scheme-window disbursement forecast Rs 350 crore across the two categories, with the Section 92BA specified-domestic-transaction register set up for the intra-group API transfer from the Cat 2 entity to the Cat 1 entity per Rule 10D documentation.

Common reconciliation breakages

Five breakages recur across PLI Pharma category-selection decision matrices, and each maps to a specific control failure.

• Product-basket fitment misclassification. The applicant tags a candidate product to Category 1 (complex generics) on an initial internal review, and the DoP Project Management Agency during application scrutiny reclassifies the product to Category 3 (other drugs not covered in Categories 1 or 2) — the incentive rate collapses from 10 percent to 5 percent and the scheme-window disbursement forecast halves. The reconciliation discipline is that each candidate product carries a documented complex-generics or patented-drug or orphan-drug definitional test — evidence trail against the DoP scheme guideline definition, therapy classification, and comparable approved products — that survives PMA scrutiny.

• FY 2019-20 base-year reconstruction gap. The applicant’s ERP material master has been re-coded since FY 2019-20 — a merger, a system migration, or an internal SKU rationalisation has broken the material-code continuity between the FY 2019-20 sales ledger and the current ERP. The base-year reconstruction then relies on manual mapping that is fragile at PMA scrutiny. The discipline is a documented material-code crosswalk from the FY 2019-20 ERP state to the current state, cross-validated against the FY 2019-20 GSTR-1 filings and the audited financial statements — the same crosswalk that Terra Insight’s reconciliation failure-mode analysis for India framework treats as a specific failure mode with a documented control test.

• Category 2 KSM DVA slippage not modelled forward. The applicant clears the 50 percent Domestic Value Addition floor in the historical years and enters Category 2 KSM approval, but the forward supply-chain plan does not model a plausible imported-input escalation scenario (a China supply disruption, a currency shift, a domestic supplier failure) — DVA slippage in Year 3 or Year 4 knocks the applicant below the 50 percent floor for that year and the KSM incentive claim for the affected year is denied. Reconciliation discipline requires a stress-tested forward DVA projection at scheme entry, with the imported-input percentage sensitivity mapped and the fall-back to Category 3 (if the KSM eligibility fails) documented in the operating plan.

• Section 115BAA opt-in without R&D pool modelling. The applicant opts into Section 115BAA on a general tax-planning recommendation before running the Section 35(2AB) forfeiture arithmetic against the actual pharma R&D pool — the concessional 22 percent rate looks attractive at headline level but destroys value net of the weighted-deduction loss for a Category 1 R&D-heavy applicant. The recommendation of the Section 35(2AB) weighted deduction pharma R&D reconciliation guide is to run the opt-in impact model as a distinct arithmetic layer in the category-selection matrix and re-evaluate at each material shift in the R&D expenditure or PLI incremental-sales trajectory.

• Section 92BA intra-group transfer gap on Cat 1 + Cat 2 parallel approvals. The applicant approved under both Category 1 (formulation) and Category 2 (API) in the same corporate group runs intra-group API transfers from the Cat 2 entity to the Cat 1 entity without setting up the Section 92BA specified-domestic-transaction register or Rule 10D transfer-pricing documentation. The gap surfaces at the statutory audit cycle or the transfer-pricing officer scrutiny cycle and can trigger a Section 271AA penalty for documentation failure. Discipline requires the intra-group transfer register to be set up at scheme entry alongside the category approvals, with the loan-licensing manufacturing and pharma CDMO reconciliation guide framework applied to intra-group formulation-plus-API transfers.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the applicant’s SAP FI or Oracle Fusion material-code sales history, the FY 2019-20 GSTR-1 archive, the DSIR-approved R&D expenditure ledger, the imported-input Bill of Entry register, and the DoP category definitions — and produces a five-layer category-selection decision matrix per candidate product basket that closes the loop from candidate-product register to ranked category recommendation. The platform applies the category-specific incentive-rate schedule, binds the per-applicant per-year cap, runs the Section 115BAA opt-in impact model against the Section 35(2AB) weighted-deduction forfeiture, and hands over the recommended category approval to the operational PLI claim workflow — category-wise product master, category-wise quarterly claim workbook, category-wise statutory-auditor certificate schedule. Match rate improvement of 51 to 88 percent on the FY 2019-20 base-year reconstruction and the candidate-product ERP material-code mapping, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling on AWS Mumbai infrastructure, is what makes the platform an infrastructure investment for a Tier 2 pharma applicant running a multi-category PLI decision matrix at scheme entry rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The PLI Pharma category-selection matrix in this depth article sits alongside the operational Category 1 quarterly claim reconciliation elaborated in the PLI Pharma Rs 15,000 crore eligibility and incremental sales reconciliation cornerstone. The R&D-side tax interaction — Section 35(2AB) weighted deduction versus Section 115BAA concessional-regime forfeiture — is the subject of the Section 35(2AB) weighted deduction pharma R&D reconciliation guide. The intra-group transfer discipline that applies when a Cat 1 formulation entity and a Cat 2 API entity in the same corporate group run parallel approvals is walked through in the loan-licensing manufacturing and pharma CDMO reconciliation guide. The methodology framework for structuring the category-selection decision matrix as a controlled reconciliation surface — with the FY 2019-20 base-year reconstruction and the DVA computation each treated as a documented failure-mode-tested control — is set out in Terra Insight’s reconciliation failure-mode analysis for India pillar. The commercial pillar for the entire pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.

The five FAQs below address the operational questions pharma controllers and PLI scheme compliance leads ask most often when running the Category 1 versus Category 2 versus Category 3 decision matrix at scheme entry.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 16 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024